EPS for AngioDynamics, Inc. (ANGO) Expected At $0.20

March 19, 2018 - By Adrian Mccoy

 EPS for AngioDynamics, Inc. (ANGO) Expected At $0.20
Investors sentiment decreased to 1.17 in 2017 Q3. Its down 1.32, from 2.49 in 2017Q2. It is negative, as 13 investors sold AngioDynamics, Inc. shares while 52 reduced holdings. 24 funds opened positions while 52 raised stakes. 33.36 million shares or 0.00% more from 33.36 million shares in 2017Q2 were reported.
Price T Rowe Assoc Md invested 0% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Ls Inv Advsrs Llc owns 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 1,331 shares. Royal State Bank Of Canada owns 116,262 shares. Trexquant Limited Partnership stated it has 0.04% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Barclays Public Limited Co stated it has 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Secor Cap Advisors Lp reported 0.16% in AngioDynamics, Inc. (NASDAQ:ANGO). First Tru Advisors L P owns 28,898 shares for 0% of their portfolio. Bridgeway Capital Mngmt Incorporated owns 137,600 shares or 0.03% of their US portfolio. Wellington Group Llp reported 25,752 shares. Amer Intl Group stated it has 28,934 shares. Gamco Invsts Et Al reported 50,000 shares. Texas Permanent School Fund accumulated 0.01% or 26,706 shares. Principal Gp owns 0% invested in AngioDynamics, Inc. (NASDAQ:ANGO) for 293,833 shares. 43,720 were accumulated by Ny State Common Retirement Fund. Alliancebernstein Limited Partnership, New York-based fund reported 159,540 shares.

Analysts expect AngioDynamics, Inc. (NASDAQ:ANGO) to report $0.20 EPS on March, 29 before the open.They anticipate $0.01 EPS change or 5.26 % from last quarter’s $0.19 EPS. ANGO’s profit would be $7.35 million giving it 21.08 P/E if the $0.20 EPS is correct. After having $0.16 EPS previously, AngioDynamics, Inc.’s analysts see 25.00 % EPS growth. The stock increased 0.30% or $0.05 during the last trading session, reaching $16.86. About 743,468 shares traded or 219.49% up from the average. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 31.47% since March 19, 2017 and is uptrending. It has outperformed by 14.77% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 8 analysts covering AngioDynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 7 Hold. Therefore 13% are positive. AngioDynamics had 20 analyst reports since July 24, 2015 according to SRatingsIntel. The firm earned “Equal Weight” rating on Wednesday, February 8 by Barclays Capital. The company was maintained on Thursday, January 4 by Canaccord Genuity. As per Wednesday, September 23, the company rating was initiated by Sidoti. The rating was initiated by Cantor Fitzgerald on Friday, November 4 with “Buy”. On Monday, July 10 the stock rating was maintained by Canaccord Genuity with “Hold”. The stock of AngioDynamics, Inc. (NASDAQ:ANGO) earned “Overweight” rating by KeyBanc Capital Markets on Friday, July 24. The firm has “Hold” rating by KeyBanc Capital Markets given on Thursday, September 28. Canaccord Genuity maintained the stock with “Buy” rating in Friday, January 8 report. Craig Hallum downgraded the stock to “Hold” rating in Friday, January 5 report. As per Sunday, October 8, the company rating was maintained by Canaccord Genuity.

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company has market cap of $619.53 million. The firm provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It currently has negative earnings. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: